Previous 10 | Next 10 |
Additional follow-up from the completed Phase 1/2 Northstar (HGB-204) study of LentiGlobin in adolescents and adults with TDT New data from ongoing Phase 3 Northstar-2 (HGB-207) study of LentiGlobin for TDT in patients who do not have β 0 /β 0 genotype and Phase ...
Bluebird bio (NASDAQ: BLUE ) downgraded to Neutral with a $131 (3% upside) price target at Wedbush. Shares down 1% premarket. More news on: bluebird bio, Inc., electroCore, Inc., Henry Schein, Inc., Healthcare stocks news, , Stocks on the move, Read more ...
New Collaboration with Seattle Children’s Research Institute Targets New Immunotherapy Approaches to Acute Myeloid Leukemia Phase 1/2 Study for Merkel Cell Carcinoma Planned with Fred Hutchinson Cancer Research Center Additional Preclinical Programs Across Both the Severe G...
With a collaboration agreement with Eli Lilly (LLY) and well-known pharma players among shareholders, NextCure (NXTC) is a name that should be assessed carefully. The company expects to have an enterprise value of $127 million, which appears to be low as compared to other peers. Keep in mind t...
Gene therapy has been the hyped technology in the biotech sector ever since the CAR-T momentum started to fade. The recent acquisitions of Spark Therapeutics ( ONCE ) and Nightstar Therapeutics ( NITE ) has many investors looking into this groundbreaking segment for a lucrative investment in t...
Biogen ( BIIB ) - The company announced interim results from a phase 1/2 study of tofersen (antisense oligonucleotide) being studied for the treatment of amyotrophic lateral sclerosis ((ALS)). Data was sufficiently encouraging to support initiation of phase 3 study in SOD1-ALS patients and ...
Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday (you c...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A trade agreement could be announced next week between the U.S. and China to end th...
bluebird bio, Inc . (Nasdaq: BLUE) today announced that the Company will host an Analyst Day, Thursday, May 9, at 8:30 am ET at The Maxwell Hotel NYC, New York, NY. In addition, members of the management team will present at the Bank of America Merrill Lynch Health Care Conference 2019,...
bluebird bio (NASDAQ: BLUE ): Q1 GAAP EPS of -$2.99 misses by $0.16 . Revenue of $12.5M (-21.7% Y/Y) misses by $2.99M . Press Release More news on: bluebird bio, Inc., Earnings news and commentary, Healthcare stocks news,
News, Short Squeeze, Breakout and More Instantly...
The downtrodden biotech space has kicked off the second half of 2022 with a boom. Hard-hit gene-editing and gene therapy companies in particular have started the back half of the year on the right foot. Underscoring this point, Bluebird Bio (NASDAQ: BLUE) stock has already risen by ...
Bluebird Bio 's (NASDAQ: BLUE) stock motored upward above 24% amid an unusually high volume of trading before pulling back to around 13.3% by noon on Tuesday, likely as a result of a short squeeze . More than 34.6% of its floating shares were held short as of June 15, which puts...